言語を選択

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)

HLA-A*1101 & B2M & EBV (AVFDRKSDAK) 製品リスト

属性
Protein (2)
製品ライブラリ
オンライン (2)
種
Human (2)
タグ
His Tag & Avi Tag (1)His Tag (1)
マーカー
Biotin-labeled (1)PE Labeled (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
HLE-H82E5	Human	HEK293	Biotinylated Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Complex Protein (Monomer, MALS verified)
HLE-HP2H4	Human	HEK293	PE-Labeled Human HLA-A*11:01&B2M&EBV (AVFDRKSDAK) Tetramer Protein

総数量2

HLA-A*1101 & B2M & EBV (AVFDRKSDAK)バックグランド

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research. The Human HLA-A*1101 EBV (AVFDRKSDAK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M and AVFDRKSDAK peptide of the EBV.

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Kidney Neoplasms; Liver Neoplasms; Solid tumours; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Neoplasms; Skin Neoplasms; Mesothelioma; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung	詳細

市販薬剤に関する情報

英語名	研究コード	研究開発ステージ	会社	オリジナル製品名	最初に承認をした国	最初の適応症	最初に承認を受けた会社	承認された日付	適応症	臨床試験
Lifitegrast	SHP-606; SAR-1119; SAR-1118; OJL-332; SPD-606	Approved	Shire Development Llc	Xiidra	United States	Dry Eye Syndromes	Bausch And Lomb Inc	2016-07-11	Keratoconjunctivitis Sicca; Graft vs Host Disease; Dry Eye Syndromes; Diabetic macular oedema; Conjunctivitis, Allergic; Xerophthalmia	詳細